Search research articles
Contact Us
Filters
Showing results (341-350 of 410) with videos related to
Page
of 41
Sort By:
Nature Communications
|
October 30, 2022
The cell-free DNA methylome captures distinctions between localized and metastatic prostate tumors
Sujun Chen, Jessica Petricca, Wenbin Ye, et al.
European Urology
|
December 12, 2018
Cabozantinib Versus Mitoxantrone-prednisone in Symptomatic Metastatic Castration-resistant Prostate Cancer: A Randomized Phase 3 Trial with a Primary Pain Endpoint
Ethan M Basch, Mark Scholz, Johann S de Bono, et al.
Nature
|
July 21, 2022
Deep whole-genome ctDNA chronology of treatment-resistant prostate cancer
Cameron Herberts, Matti Annala, Joonatan Sipola, et al.
Nature Medicine
|
October 7, 2025
Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial
Gerhardt Attard, Neeraj Agarwal, Julie N Graff, et al.
Cancer Research
|
December 9, 2024
Plasma Cell-Free DNA Chromatin Immunoprecipitation Profiling Depicts Phenotypic and Clinical Heterogeneity in Advanced Prostate Cancer
Joonatan Sipola, Aslı D Munzur, Edmond M Kwan, et al.
Nature Communications
|
April 8, 2026
SMARCB1 missense mutants disrupt SWI/SNF complex stability and remodeling activity
Garrett W Cooper, Benjamin P Lee, Won Jun Kim, et al.
Lancet (London, England)
|
July 11, 2021
Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial
Christopher Sweeney, Sergio Bracarda, Cora N Sternberg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 26, 2026
A first-in-pediatric study of ALRN-6924, a novel stapled-peptide dual MDM2/MDMX inhibitor, for children with advanced hematologic and solid malignancies
David S Shulman, Kieuhoa T Vo, Frank M Balis, et al.
Future Oncology (London, England)
|
June 19, 2026
Outcomes of a Canadian real-world cohort of metastatic castration-sensitive prostate cancer patients stratified by early PSA nadir
Michael Ong, Christopher Morash, Robert J Hamilton, et al.
Journal of the National Cancer Institute
|
May 25, 2023
Tazemetostat for tumors harboring SMARCB1/SMARCA4 or EZH2 alterations: results from NCI-COG pediatric MATCH APEC1621C
Susan N Chi, Joanna S Yi, P Mickey Williams, et al.
Page
of 41
Search research articles
Search
Showing results (341-350 of 410) with videos related to
Sort By:
Page
of 41
Nature Communications
|
October 30, 2022
The cell-free DNA methylome captures distinctions between localized and metastatic prostate tumors
Sujun Chen, Jessica Petricca, Wenbin Ye, et al.
European Urology
|
December 12, 2018
Cabozantinib Versus Mitoxantrone-prednisone in Symptomatic Metastatic Castration-resistant Prostate Cancer: A Randomized Phase 3 Trial with a Primary Pain Endpoint
Ethan M Basch, Mark Scholz, Johann S de Bono, et al.
Nature
|
July 21, 2022
Deep whole-genome ctDNA chronology of treatment-resistant prostate cancer
Cameron Herberts, Matti Annala, Joonatan Sipola, et al.
Nature Medicine
|
October 7, 2025
Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial
Gerhardt Attard, Neeraj Agarwal, Julie N Graff, et al.
Cancer Research
|
December 9, 2024
Plasma Cell-Free DNA Chromatin Immunoprecipitation Profiling Depicts Phenotypic and Clinical Heterogeneity in Advanced Prostate Cancer
Joonatan Sipola, Aslı D Munzur, Edmond M Kwan, et al.
Nature Communications
|
April 8, 2026
SMARCB1 missense mutants disrupt SWI/SNF complex stability and remodeling activity
Garrett W Cooper, Benjamin P Lee, Won Jun Kim, et al.
Lancet (London, England)
|
July 11, 2021
Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial
Christopher Sweeney, Sergio Bracarda, Cora N Sternberg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 26, 2026
A first-in-pediatric study of ALRN-6924, a novel stapled-peptide dual MDM2/MDMX inhibitor, for children with advanced hematologic and solid malignancies
David S Shulman, Kieuhoa T Vo, Frank M Balis, et al.
Future Oncology (London, England)
|
June 19, 2026
Outcomes of a Canadian real-world cohort of metastatic castration-sensitive prostate cancer patients stratified by early PSA nadir
Michael Ong, Christopher Morash, Robert J Hamilton, et al.
Journal of the National Cancer Institute
|
May 25, 2023
Tazemetostat for tumors harboring SMARCB1/SMARCA4 or EZH2 alterations: results from NCI-COG pediatric MATCH APEC1621C
Susan N Chi, Joanna S Yi, P Mickey Williams, et al.
Page
of 41